Cerevance Achieves Key Endpoints in Phase... - Cure Parkinson's
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN42
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Cough syrup drug being trialed as Parkinson’s treatment
https://neurosciencenews.com/parkinsons-ambroxol-15712/
Ambroxol, a medication approved to treat...
Must Read: Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease 24 June 2022
Novel Therapeutic Target for Parkinson’s Disease...
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial
sounds promising what do you think?
https://www.sciencealert.com/parkinsons-drug-reduces-disease-m
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
in 2019 and contemplates starting the two year Phase III trial in October of 2019, but the video...
